ClinicalTrials.gg
CompletedNCT02084875Updated Nov 30, 2018

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

A Phase 1 interventional study of tofacitinib modified-release (MR) formulation and tofacitinib modified-release (MR) formulation in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-30.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the drug behavior and safety of a single dose of the 11 milligram tofacitinib (CP-690,550) modified-release formulation in 24 healthy volunteers when taken after eating a high fat meal (the effect of food). This will be compared to the drug behavior and safety of a single dose of the 11 milligram tofacitinib (CP-690,550) modified-release formulation when taken after a 10 hour fast.

02

Conditions studied

  • Healthy

Keywords

  • Food effect
  • pharmacokinetic
  • healthy volunteer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers and/or healthy females volunteers of non- who are 18 to 55 years of age;
  • Healthy volunteers who are of Japanese or Western descent;
  • Healthy volunteers with no evidence of active or latent or inadequately treated tuberculosis.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease;
  • Clinically significant infections within the past 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    tofacitinib MR 11 mg Fed

    tofacitinib modified release (MR) 11 mg tablet administered with food.

    Drug: tofacitinib modified-release (MR) formulation

  • Experimental
    tofacitinib MR 11 mg Fasting

    tofacitinib modified release (MR) 11 mg tablet administered without food.

    Drug: tofacitinib modified-release (MR) formulation

Interventions

  • Drugtofacitinib modified-release (MR) formulation

    A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.

  • Drugtofacitinib modified-release (MR) formulation

    tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.

06

What researchers measure

Primary outcomes

  1. Area under the curve from time zero to infinity

    Area under the curve from time zero to infinity

    Time frame: 48 hours post dose

  2. Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration

    Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration

    Time frame: 48 hours post dose

  3. Maximum Observed Plasma Concentration (Cmax)

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: 48 hours post dose

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time to peak concentration

    Time frame: 48 hours post dose

  2. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 48 hours post dose

07

Study locations

1 site
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in May 2014, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2014
First posted
Mar 12, 2014
StartActual
Apr 11, 2014
Primary completionActual
May 25, 2014
CompletionActual
May 25, 2014
Last update
Nov 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02084875
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 12, 2014
Start date
Apr 11, 2014
Primary completion
May 25, 2014
Completion
May 25, 2014
Last update
Nov 30, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion